The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Prices are still high, and the Trump administration may still force the Fed to push rates lower. On the other hand ... of the ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...